World Health Organization evaluates between 200 and 300 million, the number of people who are visually impaired by diseases against which pharmaceutical treatments are however existing. Many of these conditions have in common to cause permanent vision loss if they are not treated consistently.
The lack of adherence to prescription eye drops is the #1 Unmet Medical need in Ophthalmology. Poor treatment Compliance and Adhesion leads to a worse progression of Eye Diseases. BIOPHTA wants to change the lives of patients suffering from chronic eye diseases by creating a best-in-class solution to reduce the burden of treatments.
We develop a new way of treating the eye, with a novel pharmaceutical platform enabling a continuous Drug Delivery.
Our topical Mucoadhesive Ocular Hydrogel Insert releases drugs on the eye for a one-week period, causing higher efficacy & potency for medications. These Ocular Inserts will help patients to improve their adherence to treatment regimens. It also permits a better yield of the drugs by diminishing the frequency and complexity of eye drops application while generating a continuous and controlled sustained release.
BIOPHTA non-invasive topical ocular inserts are aimed at several ophthalmic indications by allowing better long-term control of diseases.
The lack of adherence to prescription eye drops is the #1 Unmet Medical need in Ophthalmology. Poor treatment Compliance and Adhesion leads to a worse progression of Eye Diseases. BIOPHTA wants to change the lives of patients suffering from chronic eye diseases by creating a best-in-class solution to reduce the burden of treatments.
We develop a new way of treating the eye, with a novel pharmaceutical platform enabling a continuous Drug Delivery.
Our topical Mucoadhesive Ocular Hydrogel Insert releases drugs on the eye for a one-week period, causing higher efficacy & potency for medications. These Ocular Inserts will help patients to improve their adherence to treatment regimens. It also permits a better yield of the drugs by diminishing the frequency and complexity of eye drops application while generating a continuous and controlled sustained release.
BIOPHTA non-invasive topical ocular inserts are aimed at several ophthalmic indications by allowing better long-term control of diseases.
Location: France, Ile-de-France, Paris
Employees: 1-10
Total raised: $7.09M
Founded date: 2020
Investors 1
| Date | Name | Website |
| - | Agoranov | agoranov.c... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 03.06.2024 | Seed | $7.09M | - |
Mentions in press and media 5
| Date | Title | Description |
| 28.08.2024 | Leading the way: 10 promising European startups helping the blind and visually impaired | Visual impairments, including blindness and partial sight, affect millions of people worldwide, significantly impacting their ability to navigate daily life independently. These impairments can range from complete blindness to various degre... |
| 05.06.2024 | BIOPHTA Pioneers a Visionary Approach to Eye Disease Treatment | In a groundbreaking development, BIOPHTA, a cutting-edge preclinical biotech company based in Paris, has successfully secured a substantial €6.5 million in Seed funding to propel its innovative technology for treating eye diseases to new he... |
| 03.06.2024 | BIOPHTA secures €6.5M Seed funding for eye disease treatment tech | BIOPHTA, a preclinical biotech company developing technology for the treatment of eye diseases, has just closed a €6.5 million Seed round to bring its patented technology to clinical development. With a first program in the treatment of Gla... |
| 03.06.2024 | Biophta Raises €6.5M in Seed Funding | Bioptha, a Paris, France-based preclinical biotech company, raised €6.5M in Seed funding. The round was led by UI Investissement (via the Pertinence Invest 2 Fund, advised by Mérieux Equity Partners), Elaia and GO Capital, with participatio... |
| - | BIOPHTA | “Biophta – New Standard of Care for Eye Diseases” |